DCF Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

DCF Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$257K	–	92
2020 Q2	$257K	Buy	+10,000	New	+$202K	0.14%	65

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

DCF Advisers's ITCI Position: Q2 2025 in Review

DCF Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,500 shares — an estimated $462K sold.

DCF Advisers first reported a position in ITCI in Q4 2019 and held it in 22 quarters. The position peaked at $18.8M in Q4 2021. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

DCF Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
DCF Advisers sold 3,500 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $462K.
DCF Advisers first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 22 quarters.
DCF Advisers's Intra-Cellular Therapies Inc. position peaked at $18.8M in Q4 2021.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on DCF Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.